Drug Profile


Alternative Names: KPT-335

Latest Information Update: 17 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Karyopharm Therapeutics
  • Class Antivirals; Hydrazines; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Exportin-1 protein inhibitors; Nuclear export inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Viral infections

Most Recent Events

  • 01 May 2017 Anivive in-licenses verdinexor from Karyopharma
  • 16 Mar 2017 Karyopharm Therapeutics has patent protection for verdinexor in USA
  • 20 May 2015 Karyopharm Therapeutics announces intention to submit IND to the US FDA in the year 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top